SIGNATURE WORK
CONFERENCE & EXHIBITION 2022

Vaccination is the most effective public health intervention for it, but there are still multiple limitations of the influenza vaccines presently available. Due to the urgent need for a cheaper and faster vaccine design and manufacture approach to cope with the global COVID-19 pandemic, a novel immunoinformatics approach to design mRNA vaccine against SARS-CoV-2 has been proposed. Compared with the traditional approach, the strengths of immunoinformatics’ include lower cost, faster identification and screening of epitopes for vaccine design. The final vaccine design was testified to be antigenic, non-toxic, non-allergenic as well as able to trigger a robust immune response and cover a decent range of the worldwide population. Here I summarize current advances and limitations of various types of influenza A vaccine and propose a novel immunoinformatics approach to design mRNA vaccine against influenza A virus along with the future animal experiment design to further test the effectiveness of this new methodology.